Moderna announces first patient dosed in phase 1/2 study of mrna-3705 for methylmalonic acidemia

Cambridge, mass.--(business wire)--moderna announces first patient dosed in phase 1/2 study of mrna-3705 for methylmalonic acidemia.
MRNA Ratings Summary
MRNA Quant Ranking